CLOVIS ONCOLOGY INC's ticker is and the CUSIP is 189464AC4. A total of 30 filers reported holding CLOVIS ONCOLOGY INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $367,000 | -2.9% | 500,000 | 0.0% | 0.00% | – |
| Q1 2021 | $378,000 | -45.5% | 500,000 | -50.0% | 0.00% | – |
| Q4 2020 | $694,000 | -0.9% | 1,000,000 | 0.0% | 0.00% | – |
| Q3 2020 | $700,000 | -40.9% | 1,000,000 | -48.9% | 0.00% | -100.0% |
| Q2 2020 | $1,185,000 | +2.5% | 1,957,000 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $1,156,000 | -45.5% | 1,957,000 | -42.1% | 0.00% | 0.0% |
| Q4 2019 | $2,121,000 | +1.4% | 3,382,000 | -32.5% | 0.00% | 0.0% |
| Q3 2019 | $2,092,000 | +58.2% | 5,007,000 | +135.6% | 0.00% | 0.0% |
| Q2 2019 | $1,322,000 | -20.2% | 2,125,000 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $1,657,000 | -53.8% | 2,125,000 | -58.5% | 0.00% | -66.7% |
| Q4 2018 | $3,586,000 | -71.9% | 5,125,000 | -68.9% | 0.00% | -25.0% |
| Q3 2018 | $12,754,000 | +6.5% | 16,500,000 | +26.9% | 0.00% | +33.3% |
| Q2 2018 | $11,971,000 | – | 13,000,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 48,566,000 | $34,360,000 | 1.32% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 29,000,000 | $20,108,000,000 | 0.41% |
| FARALLON CAPITAL MANAGEMENT LLC | 51,910,000 | $36,077,000 | 0.22% |
| Antara Capital LP | 37,028,000 | $353,000 | 0.07% |
| CSS LLC/IL | 1,000,000 | $712,000 | 0.03% |
| ARISTEIA CAPITAL, L.L.C. | 1,463,000 | $1,037,000 | 0.03% |
| Allianz Asset Management GmbH | 29,945,000 | $21,044,000 | 0.02% |
| CAPSTONE INVESTMENT ADVISORS, LLC | 7,500,000 | $5,315,000 | 0.02% |
| D. E. Shaw & Co., Inc. | 23,550,000 | $16,725,000 | 0.02% |
| AMERIPRISE FINANCIAL INC | 42,000,000 | $29,131,000 | 0.01% |